Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment

• Verfasst von: Hasford, Joerg [VerfasserIn]
• Verfasst von: Baccarani, Michele [VerfasserIn]
• Verfasst von: Hoffmann, Verena [VerfasserIn]
• Verfasst von: Guilhot, Joelle [VerfasserIn]
• Verfasst von: Saußele, Susanne [VerfasserIn]
• Verfasst von: Rosti, Gianantonio [VerfasserIn]
• Verfasst von: Guilhot, François [VerfasserIn]
• Verfasst von: Porkka, Kimmo [VerfasserIn]
• Verfasst von: Ossenkoppele, Gert [VerfasserIn]
• Verfasst von: Lindoerfer, Doris [VerfasserIn]
• Verfasst von: Simonsson, Bengt [VerfasserIn]
• Verfasst von: Pfirrmann, Markus [VerfasserIn]
• Verfasst von: Hehlmann, Rüdiger [VerfasserIn]
• Titel: Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment
• Titelzusatz: the EUTOS score
• Verf.angabe: Joerg Hasford, Michele Baccarani, Verena Hoffmann, Joelle Guilhot, Susanne Saussele, Gianantonio Rosti, François Guilhot, Kimmo Porkka, Gert Ossenkoppele, Doris Lindoerfer, Bengt Simonsson, Markus Pfirrmann, and Rudiger Hehlmann
• E-Jahr: 2011
• Jahr: [2011]
• Umfang: 7 S.
• Illustrationen: Diagramme
• Fussnoten: Prepublished online as Blood first edition paper, May 2, 2011 ; Gesehen am 31.08.2022
• Titel Quelle: Enthalten in: Blood
• Ort Quelle: Washington, DC : American Society of Hematology, 1946
• Jahr Quelle: 2011
• Band/Heft Quelle: 118(2011), 3, Seite 686-692
• ISSN Quelle: 1528-0020
• DOI: doi:10.1182/blood-2010-12-319038
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1815456981

Abstract

The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML is still evaluated using prognostic scores developed in the chemotherapy and interferon era. The present work describes a new prognostic score that is superior to the Sokal and Euro scores both in its prognostic ability and in its simplicity. The predictive power of the score was developed and tested on a group of patients selected from a registry of 2060 patients enrolled in studies of first-line treatment with imatinib-based regimes. The EUTOS score using the percentage of basophils and spleen size best discriminated between high-risk and low-risk groups of patients, with a positive predictive value of not reaching a CCgR of 34%. Five-year progression-free survival was significantly better in the low- than in the high-risk group (90% vs 82%, P = .006). These results were confirmed in the validation sample. The score can be used to identify CML patients with significantly lower probabilities of responding to therapy and survival, thus alerting physicians to those patients who require closer observation and early intervention.